Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
A facts-only brief, written by a local AI model from this article in The Wall Street Journal, November 16, 2026. It may contain mistakes, and it is not the article: the full story is at wsj.com.
Johnson & Johnson announced on Monday that it will acquire Ollin Biosciences for an initial $2.2 billion, a transaction that includes over $1.12 billion in potential milestone payments. The deal secures OLN324, an investigational bispecific antibody designed to treat retinal vascular diseases such as wet age-related macular degeneration and diabetic macular edema. Blackstone Life Sciences will contribute $750 million over several years to fully fund the Phase 3 development of this lead asset. In return for this investment, Blackstone will receive regulatory and sales milestone payments along with single-digit royalties on future sales. The acquisition is expected to close by the end of the year and will expand Johnson & Johnson’s existing ophthalmology portfolio.
Background
- Ollin Biosciences was incubated by Arch Venture Partners and launched last year with $100 million in initial financing led by Arch, Mubadala Capital, and Monograph Capital.
- The company raised an additional $330 million in a Series B financing round in June, co-led by Arch and new investor TCGX.
- Blackstone Life Sciences, which manages $18 billion in assets, previously agreed in February to help fund the development of Johnson & Johnson’s bleximenib drug candidate for acute myeloid leukemia.
- Johnson & Johnson’s current ophthalmology business includes products for surgical vision, contact lenses, and ocular surface care.
Read the full article at wsj.com
More from Monday, November 16:
Write a comment